Beta-Blocker Use in Uncomplicated Hypertension
Beta-blockers are not recommended as first-line antihypertensive therapy for uncomplicated hypertension without a specific cardiovascular indication. [1] Adding low-dose bisoprolol solely for a resting electrocardiogram that is normal and a resting heart rate above 60 beats/min is not indicated in the absence of another beta-blocker–responsive condition. [1],[3] A systolic blood pressure of at least 110 mm Hg does not constitute a beta-blocker–specific indication in uncomplicated hypertension. [1]
Medication Selection Algorithm
When antihypertensive pharmacotherapy is indicated for hypertension without compelling indications for a specific agent, initial therapy should be selected from the following classes. [1]
- Thiazide-type diuretics (including chlorthalidone and hydrochlorothiazide). [1]
- Calcium channel blockers (including dihydropyridine agents such as amlodipine). [1]
- Angiotensin-converting enzyme inhibitors (including lisinopril). [1]
- Angiotensin receptor blockers (including losartan). [1]
Beta-blockers should be reserved for specific indications (examples include heart failure, angina, post–myocardial infarction, and heart-rate or rhythm control for certain arrhythmias). [1],[3]
Monotherapy Versus Combination Therapy
Monotherapy is acceptable for many patients when BP is near the treatment threshold and can achieve goal with tolerability. [1] Combination therapy is recommended when BP is more elevated above goal or when monotherapy is unlikely to achieve control. [1] In either scenario, selection of beta-blockers is based on presence of a compelling indication rather than resting heart rate above 60 beats/min alone. [1],[3]
Initiation Thresholds for Hypertension Pharmacotherapy
Pharmacologic antihypertensive therapy is recommended for patients with hypertension based on guideline-defined BP thresholds and overall ASCVD risk. [1] A systolic blood pressure threshold of at least 110 mm Hg does not represent a beta-blocker–specific initiation threshold. [1]
Target Blood Pressure Goals
Treatment is directed at reaching guideline-defined BP goals for the population being treated. [1] Target selection and intensification are driven by achieved BP and tolerability rather than by resting heart rate alone when a beta-blocker is not otherwise indicated. [1]
Common Pitfalls to Avoid
Initiation of beta-blocker therapy for uncomplicated hypertension without a compelling indication increases exposure to adverse effects without guideline-supported benefit expectations for standard BP endpoint reduction compared with other first-line agents. [1],[3] Failure to match therapy to guideline-defined first-line classes delays use of agents that are recommended as initial options when no compelling indication exists. [1]
Bisoprolol-Specific Considerations
Bisoprolol is an appropriate beta-1–selective beta-blocker option for beta-blocker–responsive conditions such as heart failure with reduced ejection fraction and post–myocardial infarction care when indicated by comorbidity status. [2] Bisoprolol is not recommended as an antihypertensive add-on based on normal resting electrocardiogram and resting heart rate above 60 beats/min alone. [1],[3]
Practical Clinical Decision
Bisoprolol at 2.5 mg daily should not be added solely to address resting heart rate greater than 60 beats/min or a systolic blood pressure of at least 110 mm Hg when no compelling beta-blocker indication is present. [1],[3] A medication plan should instead be aligned with guideline-recommended first-line antihypertensive classes and BP-goal–directed titration. [1]
When Addition of a Beta-Blocker Becomes Indicated
A beta-blocker such as bisoprolol should be considered when a specific indication exists, including heart failure with reduced ejection fraction, angina, post–myocardial infarction, or clinical scenarios requiring heart-rate or rhythm control with guideline-supported benefit. [1],[2],[3]